TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Proteome Sciences ( (GB:PRM) ).
Proteome Sciences has announced the appointment of SP Angel Corporate Finance LLP as its new Nominated Adviser and sole Broker, effective immediately. This strategic move is expected to enhance the company’s development efforts and strengthen its market position, potentially benefiting stakeholders by providing improved financial guidance and support.
The most recent analyst rating on (GB:PRM) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.
Spark’s Take on GB:PRM Stock
According to Spark, TipRanks’ AI Analyst, GB:PRM is a Underperform.
Proteome Sciences’ overall stock score is significantly impacted by its poor financial performance, characterized by declining revenues, negative profitability, and high debt levels. The technical analysis further indicates a bearish trend, with the stock trading below key moving averages and weak momentum indicators. The negative P/E ratio and lack of dividend yield highlight valuation concerns, contributing to the low overall score.
To see Spark’s full report on GB:PRM stock, click here.
More about Proteome Sciences
Proteome Sciences is a company operating in the biotechnology industry, focusing on proteomics and the development of protein biomarkers for diagnostics and therapeutics. The company is listed on the AIM market and is dedicated to advancing its scientific and commercial capabilities.
Average Trading Volume: 374,833
Technical Sentiment Signal: Sell
Current Market Cap: £4.87M
Find detailed analytics on PRM stock on TipRanks’ Stock Analysis page.